ReviewJournal of neurology2006
Apoptotic cascades as possible targets for inhibiting cell death in Huntington's disease.
Review in Journal of neurology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Neuroprotective role of morin hydrate on 3-nitropropionic acid-elicited huntington's disease: in vivo investigation of RIPK1/RIPK3/MLKL necroptosis signaling pathway.Molecular medicine (Cambridge, Mass.) · 2025Article
- Neurodegenerative Diseases: New Hopes and Perspectives.Current molecular medicine · 2024Review
- Huntington's disease brain-derived small RNAs recapitulate associated neuropathology in mice.Acta neuropathologica · 2021Article
- Therapeutic Advances for Huntington's Disease.Brain sciences · 2020Review
- Insulin and Exendin-4 Reduced Mutated Huntingtin Accumulation in Neuronal Cells.Frontiers in pharmacology · 2020Article
- Hippo Signaling Pathway Dysregulation in Human Huntington's Disease Brain and Neuronal Stem Cells.Scientific reports · 2018Article
- Analysis of YFP(J16)-R6/2 reporter mice and postmortem brains reveals early pathology and increased vulnerability of callosal axons in Huntington's disease.Human molecular genetics · 2015Article
- The role of the immune system in triplet repeat expansion diseases.Mediators of inflammation · 2015Review
- Minocycline upregulates pro-survival genes and downregulates pro-apoptotic genes in experimental glaucoma.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2014Article
- Degeneration of the cerebellum in Huntington's disease (HD): possible relevance for the clinical picture and potential gateway to pathological mechanisms of the disease process.Brain pathology (Zurich, Switzerland) · 2013Article
- Inhibition of microglial activation protects hippocampal neurogenesis and improves cognitive deficits in a transgenic mouse model for Alzheimer's disease.Neuro-degenerative diseases · 2012Article
- Huntington's Disease: From Mutant Huntingtin Protein to Neurotrophic Factor Therapy.International journal of biomedical science : IJBS · 2011Article
- Similarities and differences between primary and secondary degeneration of the optic nerve and the effect of minocycline.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2011Article
- Meclizine is neuroprotective in models of Huntington's disease.Human molecular genetics · 2011Article
- Minocycline reduces astrocytic reactivation and neuroinflammation in the hippocampus of a vascular cognitive impairment rat model.Neuroscience bulletin · 2010Article
- Minocycline attenuates cognitive impairment and restrains oxidative stress in the hippocampus of rats with chronic cerebral hypoperfusion.Neuroscience bulletin · 2008Article
- Neuroprotection for Huntington's disease: ready, set, slow.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2008Review
- Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.Histology and histopathology · 2008Review
- Inhibitors of metabolism rescue cell death in Huntington's disease models.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
- Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Huntington's disease (HD) is a devastating autosomal dominant disorder characterized by progressive motor and neuropsychological symptoms. Evidence implicating the apoptotic cascades as a possible cause for the neurodegeneration seen in HD has directed researchers toward investigating therapeutic treatments targeting caspases and other proapoptotic factors. Cellular and murine models, which have demonstrated that caspase-mediated cleavage could be the cause for the neurodegeneration seen in HD, have evoked more research investigating the possible inhibition of apoptosis in HD. In particular, minocycline, a tetracycline-derived antibiotic that has been shown to increase survival in transgenic mouse models of HD, exhibits a neuroprotective feature in HD and demonstrates an anti-inflammatory as well as an anti-microbial effect by inhibiting microglial activation known to cause apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.